ONWARD Medical N.V. announced a publication in Nature Medicine using investigational ONWARD ARC Therapy to address gait challenges related to Parkinson's disease. The study participant described in the Nature Medicine publication has been living with Parkinson's disease for nearly three decades. He has a severe gait disorder that has not responded to conventional therapies.

In 2021, researchers from the Swiss Federal Institute of Technology (EPFL) and CHUV investigated the possibility that ONWARD ARC Therapy (precise, targeted electrical stimulation of the spinal cord) could address common side effects of Parkinson's disease that negatively impact mobility. The team collaborated with Dr. Erwan Bezard, a renowned neuroscientist from France's National Institute of Health and Medical Research (INSERM). After the introduction of ARC Therapy and benefitting from a few weeks of rehabilitation, the study participant was able to walk without previously noticeable gait interruptions.

This study will assist ONWARD in determining whether to conduct additional clinical trials and potentially commercialize ARC Therapy in the future for those living with Parkinson's disease.